FARM COMPUTER ADOPTION IN THE GREAT PLAINS

Computers change rapidly, yet the last survey on computer use in agriculture was in 1991. We surveyed Great Plains producers in 1995 and used logit analysis to characterize adopters and non-adopters. About 37% of these producers use computers which is consistent with the general population. We confirmed previous surveys emphasizing the importance of education, age/experience, and other farm characteristics on adoption. However, we also found that education and experience may no longer be a significant influence. Future research and education could focus on when and where computers are most needed, and therefore when adoption is most appropriate.adoption, agriculture, computers, farmers, Great Plains, logit, Farm Management,

Understanding Pharmaceutical Quality by Design

This review further clarifies the concept of pharmaceutical quality by design (QbD) and describes its objectives. QbD elements include the following: (1) a quality target product profile (QTPP) that identifies the critical quality attributes (CQAs) of the drug product; (2) product design and understanding including identification of critical material attributes (CMAs); (3) process design and understanding including identification of critical process parameters (CPPs), linking CMAs and CPPs to CQAs; (4) a control strategy that includes specifications for the drug substance(s), excipient(s), and drug product as well as controls for each step of the manufacturing process; and (5) process capability and continual improvement. QbD tools and studies include prior knowledge, risk assessment, mechanistic models, design of experiments (DoE) and data analysis, and process analytical technology (PAT). As the pharmaceutical industry moves toward the implementation of pharmaceutical QbD, a common terminology, understanding of concepts and expectations are necessary. This understanding will facilitate better communication between those involved in risk-based drug development and drug application review

Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease

BACKGROUND: Patients with atherosclerotic vascular disease remain at high risk for cardiovascular events despite effective statin-based treatment of low-density lipoprotein (LDL) cholesterol levels. The inhibition of cholesteryl ester transfer protein (CETP) by anacetrapib reduces LDL cholesterol levels and increases high-density lipoprotein (HDL) cholesterol levels. However, trials of other CETP inhibitors have shown neutral or adverse effects on cardiovascular outcomes. METHODS: We conducted a randomized, double-blind, placebo-controlled trial involving 30,449 adults with atherosclerotic vascular disease who were receiving intensive atorvastatin therapy and who had a mean LDL cholesterol level of 61 mg per deciliter (1.58 mmol per liter), a mean non-HDL cholesterol level of 92 mg per deciliter (2.38 mmol per liter), and a mean HDL cholesterol level of 40 mg per deciliter (1.03 mmol per liter). The patients were assigned to receive either 100 mg of anacetrapib once daily (15,225 patients) or matching placebo (15,224 patients). The primary outcome was the first major coronary event, a composite of coronary death, myocardial infarction, or coronary revascularization. RESULTS: During the median follow-up period of 4.1 years, the primary outcome occurred in significantly fewer patients in the anacetrapib group than in the placebo group (1640 of 15,225 patients [10.8%] vs. 1803 of 15,224 patients [11.8%]; rate ratio, 0.91; 95% confidence interval, 0.85 to 0.97; P=0.004). The relative difference in risk was similar across multiple prespecified subgroups. At the trial midpoint, the mean level of HDL cholesterol was higher by 43 mg per deciliter (1.12 mmol per liter) in the anacetrapib group than in the placebo group (a relative difference of 104%), and the mean level of non-HDL cholesterol was lower by 17 mg per deciliter (0.44 mmol per liter), a relative difference of -18%. There were no significant between-group differences in the risk of death, cancer, or other serious adverse events. CONCLUSIONS: Among patients with atherosclerotic vascular disease who were receiving intensive statin therapy, the use of anacetrapib resulted in a lower incidence of major coronary events than the use of placebo. (Funded by Merck and others; Current Controlled Trials number, ISRCTN48678192 ; ClinicalTrials.gov number, NCT01252953 ; and EudraCT number, 2010-023467-18 .)

Pricing of options on spot commodities and commodity futures contracts

UnavailableIndisponíve

FARM COMPUTER ADOPTION IN THE GREAT PLAINS

Computers change rapidly, yet the last survey on computer use in agriculture was in 1991. We surveyed Great Plains producers in 1995 and used logit analysis to characterize adopters and non-adopters. About 37% of these producers use computers which is consistent with the general population. We confirmed previous surveys emphasizing the importance of education, age/experience, and other farm characteristics on adoption. However, we also found that education and experience may no longer be a significant influence. Future research and education could focus on when and where computers are most needed, and therefore when adoption is most appropriate

A Dynamic Economic Analysis of Nitrate Leaching in Corn Production under Nonuniform Irrigation Conditions

We develop a dynamic economic model that includes control variables for both nitrogen fertilizer and irrigation water to analyze interseasonal corn production and nitrate leaching in the presence of irrigation system nonuniformity. The economic model is used to estimate profit-maximizing nutrient management plans under varying levels of system uniformity. The model is also used to appraise several policy options that have been proposed in the nitrate leaching literature as a means of regulating water quality. Investments in technology are considered, as well as limits on nitrate leaching, nitrogen fertilizer, and irrigation water. Copyright 1998, Oxford University Press.